

C-Path to host its Scientific Breakthrough Summit 2023



The graphic features a geometric, low-poly background. At the top left is the Critical Path Institute logo. Below it, the text 'SCIENTIFIC BREAKTHROUGH SUMMIT' is prominently displayed. Four logos for the consortiums are arranged horizontally: CPA-1 (Critical Path for Alpha-1 Antitrypsin Deficiency), CPLD (Critical Path for Lysosomal Disease), INC (International Neonatal Consortium), and T1D (Type 1 Diabetes Consortium). To the left, a calendar icon indicates the dates 'October 26 - 27, 2023', and a location pin icon indicates 'Westin Crystal City, Arlington, VA'. A blue button with a hand cursor icon says 'REGISTER NOW'. On the right, a collage of four images shows a scientist in a lab, a woman in a lab coat, a handshake, and a group of children.

CRITICAL PATH
INSTITUTE

**SCIENTIFIC
BREAKTHROUGH SUMMIT**

CPA-1
CRITICAL PATH FOR ALPHA-1
ANTITRYPSIN DEFICIENCY

CPLD
CRITICAL PATH FOR
LYSOSOMAL DISEASE

INC
INTERNATIONAL NEONATAL
CONSORTIUM

T1D
TYPE 1 DIABETES
CONSORTIUM

October 26 - 27, 2023

Westin Crystal City
Arlington, VA

REGISTER NOW

The summit featured presentations and panel discussions with C-Path collaborators from industry, academia, global regulatory agencies, nurses, parents and patients. The workshop:

- Explored the unmet needs and potential solutions relevant to specific aspects of type-1 diabetes, alpha-1 antitrypsin deficiency, lysosomal diseases, and neonatal indications.
- Demonstrated the critical role data sharing plays in enhancing drug development for vulnerable patient populations with conditions that require interventions early in life.
- Reviewed the current landscape of regenerative therapies, identifying regulatory opportunities that could expedite the development of such groundbreaking products.

You can view recordings from the sessions below:

Day One

[Scientific Break Through Summit Opening Remarks and Keynote from Janet Maynard](#)

[Exploring Gene and Cell-Based Theories with Peter Marks](#)

[Fireside Chat on Pediatric Global Perspective and Importance](#)

[Fireside Chat on Pediatric Impact and Future of Real-World Data and Real-World Evidence](#)

[Disease Modification in Alpha 1 Antitrypsin Deficiency](#)

[Disease Modification in Lysosomal Diseases and Bronchopulmonary Dysplasia](#)

[Persistent Issues in Pediatric Drug Development: Challenges and Opportunities](#)

[A Continuity of Drug Development for Diseases Across the Lifespan](#)
[Global Perspectives of Pediatric Drug Development](#)

Contact pediatricsAdmin@c-path.org if you have any questions.